Background illustration for clinical trials search

Ovarian Cancer Clinical Trials

Browse 1,660 ovarian cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Spermatogonial Stem Cell (SSC) Transplant and Testicular Tissue Grafting

for
Infertility, Male, Cancer, Autoimmune Disorder
Location: Pittsburgh PA
Sponsor: University of Pittsburgh

Sex: Male

Age: 0+

Code: NCT04452305

Recruiting

A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours

for
Solid Tumours
Location: Valhalla NY, New York NY, Philadelphia PA, Fairfax VA,
Sponsor: Orion Corporation, Orion Pharma

Sex: All

Age: 18+

Code: NCT06725758

Phase 1, Phase 2, Recruiting

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

for
Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
Location: Boston MA, Providence RI, Norwalk CT, New York NY,
Sponsor: Fore Biotherapeutics

Sex: All

Age: 8+

Code: NCT05503797

Phase 2, Recruiting

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy

for
Locally Advanced Cancer, Metastatic Cancer, HER2,
Location: Nashville TN
Sponsor: Vanderbilt-Ingram Cancer Center

Sex: All

Age: 18+

Code: NCT06828588

Early Phase 1, Recruiting

SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization

for
Prostate Cancer, Advanced Cancer
Location: Baltimore MD
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Sex: All

Age: 18 - 70+

Code: NCT06389097

Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors

for
Solid Tumors, Adult
Location: Plantation FL, Cleveland OH, Denver CO
Sponsor: Hutchmed

Sex: All

Age: 18+

Code: NCT07228247

Phase 1, Phase 2, Recruiting

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

for
Recurrent Glioblastoma,
Location: Bethesda MD
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Sex: All

Age: 18 - 70+

Code: NCT07416188

Phase 1, Phase 2, Recruiting

Improving Cognition and Behavior in Pediatric Cancer Survivors Using a Novel Mindful Attention Training

for
Pediatric Cancer
Location: San Francisco CA
Sponsor: University of California, San Francisco

Sex: All

Age: 7 - 17

Code: NCT05000905

Recruiting

Biofield Therapy for the Support of Immunotherapy-related Symptoms Among Adult Cancer Patients - A Pilot Study

for
Cancer, Immunotherapy, Fatigue Related to Cancer Treatment,
Location: Orange CA, Irvine CA
Sponsor: University of California, Irvine

Sex: All

Age: 18+

Code: NCT07581080

Recruiting

Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors

for
Cancer
Location: Rochester NY
Sponsor: University of Rochester

Sex: All

Age: 65+

Code: NCT07390045

Recruiting

Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A

for
Solid Tumors
Location: San Antonio TX
Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Sex: All

Age: 18+

Code: NCT03950297

Phase 1, Recruiting

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

for
Non Small Cell Lung Cancer,
Location: Boston MA, Austin, TX 78758 TX, San Antonio TX
Sponsor: Zumutor Biologics Inc.

Sex: All

Age: 18+

Code: NCT06451497

Phase 1, Recruiting

A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

for
Advanced NRAS-Mutant Melanoma,
Location: Boston MA, New York NY, Fairfax VA, Grand Rapids MI,
Sponsor: Relay Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07584226

Phase 1, Phase 2, Recruiting

Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors

for
Adenocarcinoma, Basal Cell Carcinoma, Squamous Cell Carcinoma,
Location: Orange CA
Sponsor: University of California, Irvine

Sex: All

Age: 18+

Code: NCT07628634

Early Phase 1, Recruiting

Evaluation of Grief Therapy Approaches for Bereaved Parents

for
Grief, Bereavement, Cancer
Location: New York NY, Philadelphia PA, Memphis TN, Stanford CA
Sponsor: University of Miami

Sex: All

Age: 18+

Code: NCT05142605

Recruiting

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

for
Advanced Solid Tumor, Non-Small Cell Lung Cancer,
Location: Fairfax VA, Tampa FL, Sarasota FL
Sponsor: Blueprint Medicines Corporation

Sex: All

Age: 18+

Code: NCT07629960

Phase 1, Phase 2, Recruiting

STABLE (Strength Training and Balance Leg Exercise) Study

for
Neoplasms
Location: Edmonton
Sponsor: University of Saskatchewan

Sex: All

Age: 65+

Code: NCT04518098

Recruiting

Occupational Cancer Screening in Firefighters: A Pilot Study Within the Inova Health System

for
Cancer
Location: Fairfax VA
Sponsor: Inova Health Care Services

Sex: All

Age: 35 - 70+

Code: NCT06931561

Recruiting

STING MARK Universal Fiducial Marker System

for
Cancer
Location: Montreal
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)

Sex: All

Age: 18+

Code: NCT05465161

Recruiting

Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors

for
Unspecified Adult Solid Tumor, Protocol Specific
Location: Palo Alto CA
Sponsor: Stanford University

Sex: All

Age: 18+

Code: NCT02215928

Recruiting

What is ovarian cancer?

Ovarian cancer begins in or near the ovaries. About 9 in 10 cases are epithelial, and most of those are high grade serous tumors that research now shows usually start in the fallopian tubes rather than the ovary. Rarer types begin in the egg cells or in hormone producing cells. It is hard to catch early. The ovaries sit deep in the pelvis, and early symptoms like bloating, pelvic or back pain, feeling full quickly, and urinary urgency are vague and common. The most frequent sign at diagnosis is abdominal swelling from fluid, which means the cancer is already advanced.

Treatment has changed. Surgery to remove as much tumor as possible, followed by platinum chemotherapy, is still the foundation. Since 2014 PARP inhibitor pills have been used to delay recurrence in BRCA mutated and similar tumors, and testing every patient for these mutations is now standard. In 2022 the first antibody drug conjugate for ovarian cancer was approved for platinum resistant disease, with full approval in 2024. Prevention has moved too. Because most cancers start in the tubes, removing only the fallopian tubes during other pelvic surgery is being tested as a way to prevent cancer without early menopause.

Ovarian cancer shares its inherited risk genes with breast, pancreatic, and prostate cancer. Our cancer treatment guide explains how targeted therapies work.

Types of ovarian cancer clinical trials

How is ovarian cancer diagnosed and tested?

Who can participate in ovarian cancer clinical trials?

The stages of ovarian cancer, and why they matter for trials

How to enroll in an ovarian cancer clinical trial